The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginning

The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginning

Bibliographic Details
Main Author:	Sumit Agrawal
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2020-01-01
Series:	Indian Journal of Urology
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2020;volume=36;issue=1;spage=69;epage=70;aulast=Agrawal

Similar Items

Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
by: Florian Rosar, et al.
Published: (2021-05-01)

Orbital and brain metastases on 68Ga-PSMA PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy
by: Ashwin Singh Parihar, et al.
Published: (2021-01-01)

Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: A case report
by: Letjie C. Maserumule, et al.
Published: (2021-03-01)

Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
by: Cordula A. Jilg, et al.
Published: (2020-03-01)

Total Tumor Volume on18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with225 Ac-PSMA-I&T
by: Albert, N.L, et al.
Published: (2022)

Development of [<sup>225</sup>Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
by: Eline L. Hooijman, et al.
Published: (2021-05-01)

Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples
by: Romain Schollhammer, et al.
Published: (2019-06-01)

Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)
by: Maria Luisa Belli, et al.
Published: (2020-11-01)

Evaluation of <sup>68</sup>Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617 Therapy: A Radiomics Analysis
by: Wolfgang Roll, et al.
Published: (2021-07-01)

68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
by: Jean-Philippe Sinnes, et al.
Published: (2020-11-01)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
by: Moran Gadot, et al.
Published: (2020-04-01)

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
by: Daniel Groener, et al.
Published: (2021-07-01)

Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer
by: Cristina Müller, et al.
Published: (2019-07-01)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Liam Widjaja, et al.
Published: (2021-06-01)

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy
by: Caliebe, A., et al.
Published: (2022)

Understanding the mechanism of 177Lu- PSMA617 radioligand therapy and evaluating its potential role in the treatment of metastatic castrate resistant prostate cancer (mCRPC)
by: Joshi, Jay
Published: (2020)

68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
by: Lisa H. de Vries, et al.
Published: (2020-03-01)

Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma
by: Stefan A. Koerber, et al.
Published: (2021-03-01)

Application of 68Ga-PSMA-617 Molecular Probe for Micro-PET Imaging of Gliomas Model
by: HAN Xuedi, et al.
Published: (2018-07-01)

Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
by: Madhav Prasad Yadav, et al.
Published: (2021-01-01)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
by: Magdalena Staniszewska, et al.
Published: (2021-07-01)

Outcome of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
by: Nicolai Mader, et al.
Published: (2021-08-01)

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
by: Florian Rosar, et al.
Published: (2021-05-01)

Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
by: Daniel Groener, et al.
Published: (2021-08-01)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [<sup>225</sup>Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
by: Yun Qin, et al.
Published: (2020-11-01)

[<sup>177</sup>Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative <i>In Vitro</i> Autoradiography
by: Roswitha Tönnesmann, et al.
Published: (2019-01-01)

Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
by: Florian Rosar, et al.
Published: (2021-06-01)

Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA—A Proof of Concept Study
by: Falco Reissig, et al.
Published: (2021-04-01)

Clinical perspectives of PSMA PET/MRI for prostate cancer
by: Felipe de Galiza Barbosa, et al.
Published: (2018-09-01)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
by: Konstantin Egon Seitzer, et al.
Published: (2021-07-01)

Re: The role of 68Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer
by: Yasemin Benderli Cihan

Chemotherapy and its evolving role in the management of advanced prostate cancer
by: Michael T Schweizer, et al.
Published: (2014-06-01)

PSMA-1-Doxorubicin Conjugates for Targeted Therapy of Prostate Cancer
by: Walker, Natalie
Published: (2019)

Ac-EAZY! Towards GMP-Compliant Module Syntheses of <sup>225</sup>Ac-Labeled Peptides for Clinical Application
by: Marc Pretze, et al.
Published: (2021-07-01)

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
by: Judith Stangl-Kremser, et al.
Published: (2021-08-01)

Design of a Thorium Metal Target for <sup>225</sup>Ac Production at TRIUMF
by: Andrew K.H. Robertson, et al.
Published: (2019-02-01)

Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.
by: Batool Albalooshi, et al.
Published: (2020-01-01)

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
by: Fanny Lundmark, et al.
Published: (2020-07-01)

The role of 68Ga-PSMA PET/MRI in the detection and localisation of prostate cancer: The SAMURAI study
by: J. Cheng, et al.
Published: (2020-07-01)

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility
by: E. David Crawford, et al.
Published: (2017-05-01)